Independent Analyses Of The SEAS, SHARP And IMPROVE-IT Studies Of Statin Ezetimibe
The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) proposed that the hypothesis-generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE-IT trials of ezetimibe, and reporting on the overall findings to the relevant regulatory authorities, independently of the drug manufacturers.
More: continued here
Filed under: Cholesterol on July 25th, 2008